Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in EGFR-mutant PD-L1+ NSCLC
NCT05255406Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05255406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255406.